Patents Issued in July 2, 2020
  • THERAPEUTIC DELIVERY VESICLES
    Publication number: 20200207833
    Abstract: The present invention pertains to inter alia therapeutic delivery vesicles, for instance exosomes or microvesicles, comprising polypeptide constructs, methods for producing said therapeutic delivery vesicles, pharmaceutical compositions and medical uses thereof. The therapeutic polypeptide constructs comprised in the extracellular delivery vesicles enable sequestering target molecules of interest, to treat e.g. neuro-inflammatory diseases and cancer.
    Type: Application
    Filed: February 19, 2020
    Publication date: July 2, 2020
    Inventors: Samir EL ANDALOUSSI, Oscar WIKLANDER, Joel NORDIN, Edvard SMITH, Karl-Henrik GRINNEMO, Oscar SIMONSON
  • GENE TRANSFER SYSTEMS FOR STEM CELL ENGINEERING
    Publication number: 20200207834
    Abstract: The present disclosure provides for non-viral compositions and methods for delivering nucleic acids into eukaryotic cells (e.g., stem cells) with high efficiency and low genotoxicity.
    Type: Application
    Filed: July 19, 2018
    Publication date: July 2, 2020
    Inventors: Arash HATEFI, Xuguang CHEN, Alireza NOMANI
  • SRCP1-BASED THERAPY FOR DISEASES ASSOCIATED WITH PROTEIN AGGREGATION
    Publication number: 20200207835
    Abstract: Compositions, methods and kits for the reduction of protein aggregation are provided. Further compositions, methods and kits are also provided for the treatment of diseases associated with protein aggregation, particularly polyglutamine disease, including Huntington's disease.
    Type: Application
    Filed: August 17, 2018
    Publication date: July 2, 2020
    Applicant: THE MEDICAL COLLEGE OF WISCONSIN, INC.
    Inventor: Kenneth Matthew Scaglione
  • Screening Assays, Modulators and Modulation of Activation of Receptor for Advanced Glycation End-Products (RAGE)
    Publication number: 20200207836
    Abstract: A method of screening candidate agents for their ability to modulate RAGE activity where such RAGE activity is induced by an active co-located GPCR, the method comprising the steps of: contacting a RAGE polypeptide with a GPCR polypeptide in the presence of a candidate agent where the GPCR polypeptide is constitutively active and/or is activated by addition of an agonist, partial agonist or allosteric modulator of that GPCR; and detecting whether the candidate agent is a modulator of RAGE ligand-independent activation of RAGE by activated co-located GPCR by detecting an effect indicative of modulation of RAGE activation by the presence of the candidate agent and/or by detecting RAGE-dependent signalling that is modulated by the presence of the candidate agent.
    Type: Application
    Filed: August 21, 2018
    Publication date: July 2, 2020
    Inventors: Kevin Donald George PFLEGER, Merlin Christopher THOMAS, Raelene Jane PICKERING, Carlos ROSADO, Christos TIKELLIS
  • PEPTIDES INHIBITING KLK1, KLK4, OR KLK4 AND KLK8
    Publication number: 20200207837
    Abstract: The present invention provides a novel peptide which comprises an amino acid sequence represented by SEQ ID NO: 23, and specifically inhibits the protease activity of a target molecule.
    Type: Application
    Filed: September 6, 2018
    Publication date: July 2, 2020
    Applicant: Daiichi Sankyo Company, Limited
    Inventors: Daisuke Nishimiya, Masakazu Tamura
  • SINGLE CHAIN VH AND HEAVY CHAIN ANTIBODIES
    Publication number: 20200207838
    Abstract: The present invention provides cells, transgenic animals, including transgenic mammals and particularly rodents comprising engineered immunoglobulin (Ig) alleles. Such engineered alleles, wherein an Ig light chain CL exon [C? or C? (C?1, C?2 or C?3)] is incorporated into the Ig heavy chain locus, are capable of producing heavy chain-only antibodies as a single chain VH antibody (scVHAb) or heavy chain antibody (HCAb) comprising two extended scVHAbs. The scVHAb comprises an antigen-binding part consisting of a VH domain and the immunoglobulin constant domains CL, which is either C? or C?, and CH1, in the order from N-terminus to C-terminus: VH-L1-CL-L2-CH1, wherein L1 and L2 are each, independently, peptidic linkers; and wherein CL is paired with CH1 through beta-sheet contact thereby obtaining a CL/CH1 dimer.
    Type: Application
    Filed: July 20, 2018
    Publication date: July 2, 2020
    Inventors: Werner MUELLER, Matthias WABL
  • IMMUNOGLOBULIN PURIFICATION
    Publication number: 20200207839
    Abstract: The current invention reports a method for purifying an immunoglobulin, wherein the method comprises applying an aqueous, buffered solution comprising an immunoglobulin in monomeric, in aggregated, and in fragmented form to an anion exchange chromatography material under conditions whereby the immunoglobulin in monomeric form does not bind to the anion exchange material, and recovering the immunoglobulin in monomeric form in the flow-through from the anion exchange chromatography material, whereby the buffered aqueous solution has a pH value of from 8.0 to 8.5. In one embodiment the anion exchange chromatography material is a membrane anion exchange chromatography material.
    Type: Application
    Filed: August 12, 2019
    Publication date: July 2, 2020
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Marc Pompiati, Andreas Schaubmar
  • DETECTION OF CHO-MIF CONTAMINATIONS
    Publication number: 20200207840
    Abstract: The invention concerns a detection method to enable the detection of complexes formed between antibodies and antigen which is endogenous to the production cell line, e.g. CHO MIF in a final product.
    Type: Application
    Filed: March 12, 2020
    Publication date: July 2, 2020
    Inventors: Dirk Voelkel, Patrice Douillard, Gerhard Antoine, Randolf Kerschbaumer
  • NOVEL FULL SPECTRUM ANTI-DENGUE ANTIBODY
    Publication number: 20200207841
    Abstract: The present invention provides, among other things, antibody agents (e.g., antibodies, and/or antigen-binding fragments thereof) that bind to DV epitopes, as well as compositions containing them and methods of designing, providing, formulating, using, identifying and/or characterizing them. In some embodiments, provided antibody agents show significant binding to a plurality of DV serotypes. In some embodiments, provided antibody agents show significant binding to all four DV serotypes. Such antibody agents are useful, for example, in the prophylaxis, treatment, diagnosis, and/or study of DV.
    Type: Application
    Filed: December 26, 2019
    Publication date: July 2, 2020
    Inventors: Ram Sasisekharan, Kannan Tharakaraman
  • ANTI-C5A ANTIBODIES
    Publication number: 20200207842
    Abstract: The present disclosure relates to, inter alia, antibodies, or antigen-binding fragments thereof, that bind to C5a and to use of the antibodies in methods for treating or preventing complement-associated disorders such as, but not limited to, atypical hemolytic uremic syndrome, age-related macular degeneration, rheumatoid arthritis, sepsis, severe burn, antiphospho lipid syndrome, asthma, lupus nephritis, Goodpasture's syndrome, and chronic obstructive pulmonary disease.
    Type: Application
    Filed: September 12, 2019
    Publication date: July 2, 2020
    Inventors: Russell P. ROTHER, Douglas L. SHERIDAN, Paul P. TAMBURINI, Yuchun ZHANG
  • ANTI-TAU CONSTRUCTS
    Publication number: 20200207843
    Abstract: The present invention provides anti-tau constructs. Anti-tau constructs of the invention are polynucleotide sequences encoding a polypeptide comprising at least one tau binding moiety and optionally comprising a signal peptide and/or a purification moiety. The present invention also provides isolated polypeptides encoded by anti-tau constructs, vectors comprising anti-tau constructs, and isolated cells comprising said vectors.
    Type: Application
    Filed: March 12, 2020
    Publication date: July 2, 2020
    Inventors: David HOLTZMAN, Hong JIANG, Gilbert GALLARDO, Christina ISING, Cheryl LEYNS
  • ANTI-VEGF ANTIBODY
    Publication number: 20200207844
    Abstract: This disclosure relates to antibodies and antigen-binding fragments that bind specifically to Vascular endothelial growth factor (VEGF), and prophylactic, diagnostic, and therapeutic methods of using the same.
    Type: Application
    Filed: September 11, 2018
    Publication date: July 2, 2020
    Applicant: IGC BIO, INC.
    Inventors: Dror BARAN, Lior ZIMMERMAN
  • ANG2-BINDING MOLECULES
    Publication number: 20200207845
    Abstract: Ang2-binding molecules, preferably Ang2-binding immunoglobulin single variable domains like VHHs and domain antibodies, pharmaceutical compositions containing same and their use in the treatment of diseases that are associated with Ang2-mediated effects on angiogenesis. Nucleic acids encoding Ang2-binding molecules, host cells and methods for preparing same.
    Type: Application
    Filed: March 13, 2020
    Publication date: July 2, 2020
    Inventors: Rene Georg Ott, Eric Borges, Andreas Gschwind, Joachim Boucneau, Marie-Ange Buyse, Erik Depla, Pascal Merchiers, Frederik Stevenaert
  • LIGAND-BINDING MOLECULE HAVING ADJUSTABLE LIGAND BINDING ACTIVITY
    Publication number: 20200207846
    Abstract: The present invention relates to a ligand binding molecule whose ligand binding activity is attenuated by the cleavage of a cleavage site and a method for producing the same, a complex formed by the ligand binding molecule and a ligand, a fusion protein comprising the ligand binding molecule and a ligand, and a pharmaceutical composition comprising the ligand binding molecule or a fusion protein of the ligand binding molecule and a ligand.
    Type: Application
    Filed: November 28, 2017
    Publication date: July 2, 2020
    Inventors: Tomoyuki IGAWA, Hiroyuki ISHIKAWA
  • IL-11RA ANTIBODIES
    Publication number: 20200207847
    Abstract: IL-11Ra antibodies are disclosed. Also disclosed are compositions comprising the IL-11Ra antibodies, and methods using the IL-11Ra antibodies.
    Type: Application
    Filed: December 23, 2019
    Publication date: July 2, 2020
    Applicants: Singapore Health Services PTE LTD., National University of Singapore
    Inventors: Stuart Alexander Cook, Sebastian Schaefer
  • USE OF IL-1B BINDING ANTIBODIES FOR THE TREATMENT OF ALCOHOLIC HEPATITIS
    Publication number: 20200207848
    Abstract: The present invention relates to a method for treating or alleviating the symptoms of alcoholic hepatitis in a subject, comprising administering gevokizumab or 2-5 mg of canakinumab per kg of body weight to a subject in need thereof.
    Type: Application
    Filed: September 11, 2018
    Publication date: July 2, 2020
    Inventor: Shephard MPOFU
  • NOVEL ENGINEERED T CELL RECEPTORS AND IMMUNE THERAPY USING THE SAME
    Publication number: 20200207849
    Abstract: The present invention pertains to antigen recognizing constructs against COL6A3 antigens. The invention in particular provides novel engineered T cell receptor (TCR) based molecules which are selective and specific for the tumor expressing antigen COL6A3. The TCR of the invention, and COL6A3 antigen binding fragments derived therefrom, are of use for the diagnosis, treatment and prevention of COL6A3 expressing cancerous diseases. Further provided are nucleic acids encoding the antigen recognizing constructs of the invention, vectors comprising these nucleic acids, recombinant cells expressing the antigen recognizing constructs and pharmaceutical compositions comprising the compounds of the invention.
    Type: Application
    Filed: January 7, 2020
    Publication date: July 2, 2020
    Inventors: Felix UNVERDORBEN, Sebastian BUNK, Martin HOFMANN, Dominik MAURER, Meike HUTT, Claudia WAGNER, Leonie ALTEN
  • MULTI-CHAIN POLYPEPTIDE-CONTAINING TRI-SPECIFIC BINDING MOLECULES THAT SPECIFICALLY BIND TO MULTIPLE CANCER ANTIGENS
    Publication number: 20200207850
    Abstract: The present invention relates to Tri-Specific Binding Molecules, which are multi-chain polypeptide molecules that possess three Binding Domains and are thus capable of mediating coordinated binding to three epitopes. The Binding Domains may be selected such that the Tri-Specific Binding Molecules are capable of binding to any three different epitopes. Such epitopes may be epitopes of the same antigen or epitopes of two or three different antigens. In a preferred embodiment, one of such epitopes will be capable of binding to CD3, the second of such epitopes will be capable of binding to CD8, and the third of such epitopes will be capable of binding to an epitope of a Disease-Associated Antigen. The invention also provides a novel ROR1-binding antibody, as well as derivatives thereof and uses for such compositions.
    Type: Application
    Filed: March 13, 2020
    Publication date: July 2, 2020
    Inventors: Leslie S. JOHNSON, Ling HUANG, Gurunadh Reddy CHICHILI, Kalpana SHAH, Chia-Ying Kao LAM, Stephen James BURKE, Liqin LIU, Paul A. MOORE, Ezio BONVINI, Bhaswati BARAT
  • TRIFUNCTIONAL MOLECULE AND APPLICATION THEREOF
    Publication number: 20200207851
    Abstract: This disclosure belongs to the field of biomedical technology, and particularly refers to a trifunctional molecule and the application thereof. The structure of the trifunctional molecule includes a first functional domain, a second functional domain and a third functional domain. These domains are capable of simultaneously binding to CD19, CD3, and T cell positive (negative) costimulatory factors, thereby producing the first and second signal required for T cell activation. The trifunctional molecule is a recombinant protein peptide chain, which can be produced by a eukaryotic cell expression system. The product has a single structure, simple purification process, high protein yield, and preparation process and product stability. The trifunctional molecule is superior to the anti-CD19/anti-CD3 BiTE bispecific antibody in killing CD19-positive target cells.
    Type: Application
    Filed: August 9, 2017
    Publication date: July 2, 2020
    Applicant: CYTOCARES (SHANGHAI) INC.
    Inventors: Shuai CHEN, Huaxing ZHU, Yuanping LIAO
  • T CELLS EXPRESSING A CHIMERIC ANTIGEN RECEPTOR
    Publication number: 20200207852
    Abstract: Described herein are methods for producing and utilizing T cells comprising chimeric antigen receptors (CAR) comprising an extracellular domain that binds CD79b, or CD79b and CD 19. Further, this invention is related to methods of treating cancer, plasma cell diseases or disorders, or autoimmune diseases or disorders.
    Type: Application
    Filed: June 7, 2018
    Publication date: July 2, 2020
    Inventors: Marcela V. MAUS, Maria ORMHØJ, Torben BARINGTON
  • ANTI-CD47 ANTIBODIES AND USES THEREOF
    Publication number: 20200207853
    Abstract: Anti-CD47 antibodies and antigen-binding fragments thereof are described. Also described are nucleic acids encoding the antibodies, compositions comprising the antibodies, and methods of producing the antibodies and using the antibodies for treating or preventing diseases such as cancer, inflammatory disease, infectious disease, atherosclerosis, cardiovascular disease, metabolic disease, radiation-induced injury, and/or autoimmune disease.
    Type: Application
    Filed: July 30, 2018
    Publication date: July 2, 2020
    Inventors: Minghan WANG, Hui ZOU, Joshua OAKS, Haiqun JIA
  • HUMANIZED AFFINITY MATURED ANTI-FcRn ANTIBODIES
    Publication number: 20200207854
    Abstract: Provided herein are recombinant antibodies and antigen-binding portions thereof useful for binding to FcRn and blocking binding of FcRn to IgG Fc. The FcRn-binding proteins can be used to treat a variety of disorders including autoimmune disorders.
    Type: Application
    Filed: February 25, 2020
    Publication date: July 2, 2020
    Inventors: Laurence J. Blumberg, Richard S. Blumberg, Susan D. Jones, Derry Roopenian, Robert George Edward Holgate, Timothy David Jones, Arron Robert Hearn
  • NOVEL ANTIBODIES AND COMBINED USE OF A TREG DEPLETING ANTIBODY AND AN IMMUNOSTIMULATORY ANTIBODY
    Publication number: 20200207855
    Abstract: Described is the sequential administration of first a Treg depleting antibody molecule selected from antibody molecules, such as an antibody molecule binding specifically to target belonging to the tumour necrosis factor receptor superfamily (TNFRSF), such as a Treg depleting anti-4-1 BB antibody or a Treg depleting OX-40 antibody, and then an immunostimulatory antibody molecule, such as an immunostimulatory anti-4-1 BB anti-body or an immunostimulatory OX-40 antibody, for use in the treatment of cancer. Described are also novel anti-4-1 BB antibodies and novel OX-40 antibodies that may be used in such sequential administration.
    Type: Application
    Filed: July 26, 2018
    Publication date: July 2, 2020
    Inventors: Björn FRENDÉUS, Linda MÅRTENSSON, Monika SEMMRICH, Ingrid TEIGE, Stephen BEERS, Aymen AL-SHAMKHANI, Juliet GRAY, Martin GLENNIE
  • ANTIBODIES TO LILRB2
    Publication number: 20200207856
    Abstract: Provided herein are various embodiments relating to antibodies that bind LILRB2. Anti-LILRB2 antibodies can be used in methods to treat disease, for example, cancer.
    Type: Application
    Filed: March 11, 2020
    Publication date: July 2, 2020
    Inventors: Heather B. Cohen, Lauren Pepper MacKenzie, Yasmin Ramsay, Donald Raymond Shaffer, Jeffrey Yan-Fei Smith, Kristin Shanea O'Malley, Kevin Patrick Guay
  • BINDING MOLECULES SPECIFIC FOR CLAUDIN 18.2, COMPOSITIONS AND METHODS THEREOF, FOR THE TREATMENT OF CANCER AND OTHER DISEASES
    Publication number: 20200207857
    Abstract: Compositions and methods of making isolated binding molecules (e.g. an antibodies) or antigen-binding fragment thereof useful as therapeutics for treating and/or preventing diseases associated with cells expressing claudin18.2, including tumor-related diseases such as gastric cancer, esophageal cancer, pancreatic cancer, lung cancer, ovarian cancer, colon cancer, hepatic cancer, head-neck cancer, and cancer of the gallbladder are described. Also, described are pharmaceutical formulations comprising the described compositions for the treatment of diseases either as single agent (e.g., naked antibodies) or as adjuvant therapy with other antigen-binding anticancer agents such as immune checkpoint inhibitors (e.g., anti-CTLA-4 and anti-PD-1/PD-L1 monoclonal antibodies), and/or by combination therapies where the anti-claudin18.2 antibodies are administered before, after, or concurrently with chemotherapy.
    Type: Application
    Filed: December 26, 2019
    Publication date: July 2, 2020
    Applicant: Sparx Therapeutics Inc.
    Inventors: Guidong Zhu, Jingdong Ye, Jingdong Qin, Jichun Ma
  • ANTIBODIES CAPABLE OF BINDING HLA-A2/TYRD IN AN HLA RESTRICTED MANNER AND USES THEREOF
    Publication number: 20200207858
    Abstract: Antibodies capable of binding HLA-A2/Tyrosinase (TyrD) in an HLA restricted manner are provided. Specifically, the antibodies are capable of binding HLA-A2/TyrD369-377 in an HLA restricted manner. Further provided are complementary determining region (CDR) sequences of heavy chain and light chain of antibodies, and methods of using the antibodies for the treatment of cancer.
    Type: Application
    Filed: June 14, 2017
    Publication date: July 2, 2020
    Inventors: Aya Jakobovits, Orit FOORD, Daulet Kadyl Satpayev, Mira Peled Kamar, Galit Denkberg, Yoram Reiter, Ilan Beer, Keren Sinik, Yael Teboul (Elbaz), Yael Shperber (Sery), Reut Erel Segal, Ravit Oren, Dror Shmuel Alishekevitz
  • METHODS OF USING ANTI-CD74 ANTIBODIES AND ANTIBODY CONJUGATES IN TREATMENT OF T-CELL LYMPHOMA
    Publication number: 20200207859
    Abstract: Provided herein are antibody conjugates with binding specificity for CD74 and compositions comprising the antibody conjugates, including pharmaceutical compositions, methods of producing the conjugates, and methods of using the conjugates and compositions for therapy involving treatment, amelioration, and/or diagnosis of a T-cell lymphoma.
    Type: Application
    Filed: July 25, 2018
    Publication date: July 2, 2020
    Inventor: Arturo MOLINA
  • EXTRA LUMINAL SCAFFOLD
    Publication number: 20200207860
    Abstract: Methods and devices for treating a luminal pathology affecting an anatomical lumen of a patient comprising forming, in situ, a continuous cohesive layer of covalently-crosslinked hydrogel in a luminal wall of the anatomical lumen.
    Type: Application
    Filed: December 19, 2019
    Publication date: July 2, 2020
    Inventors: Amarpreet S. Sawhney, Farhad Khosravi, Patrick Campbell
  • METHOD OF INHIBITION OF LEUKEMIC STEM CELLS
    Publication number: 20200207861
    Abstract: A method for inhibition of leukemic stem cells expressing IL-3R? (CD123), comprises contacting the cells with an antigen binding molecule comprising a Fc region or a modified Fc region having enhanced Fc effector function, wherein the antigen binding molecule binds selectively to IL-3R? (CD123). The invention includes the treatment of a hematologic cancer condition in a patient by administration to the patient of an effective amount of the antigen binding molecule.
    Type: Application
    Filed: July 19, 2019
    Publication date: July 2, 2020
    Applicants: CSL Limited, University Health Network
    Inventors: John Edgar DICK, Liqing Jin, Gino Luigi VAIRO, David Paul Gearing, Samantha Jane Busfield
  • ANTI-IL-36R ANTIBODIES FOR TREATMENT OF PALMOPLANTAR PUSTULOSIS
    Publication number: 20200207862
    Abstract: The present invention relates to the treatment of or alleviation of signs and symptoms of palmoplantar pustulosis (PPP) with anti-IL-36R antibodies in a patient.
    Type: Application
    Filed: December 20, 2019
    Publication date: July 2, 2020
    Inventors: Patrick BAUM, Janine LAMAR, Steven John PADULA, Christian THOMA
  • HUMAN BLADDER CANCER MARKER AG-CD71 AND ANTIBODY ABC71 AND APPLICATION THEREOF
    Publication number: 20200207863
    Abstract: A novel human bladder cancer marker AG-CD71 and a monoclonal antibody ABC71 for preventing AG-CD71 are provided. The human bladder cancer marker AG-CD71 is an abnormal glycosylated transferrin receptor TFRC; the abnormal glycosylated transferrin receptor TFRC refers to the TFRC carrying a saccharide structure Fucal-4(GlcNAcbl-3)[6OSO3]GlcNAc as an epitope. Also provided is an antibody for the human bladder cancer marker AG-CD71; the antibody is the monoclonal antibody ABC71 specific for the human bladder cancer AG-CD71; the monoclonal antibody is secreted from the hybridoma cell to strain the preservation number of which is CGMCC No. 14312.
    Type: Application
    Filed: May 30, 2018
    Publication date: July 2, 2020
    Inventor: Chong LI
  • METHODS FOR TREATING NEPHROTIC SYNDROME
    Publication number: 20200207864
    Abstract: Described herein are methods for treating nephrotic syndrome using an anti-CD20 antibody. In one embodiment, that anti-CD20 antibody is Obinutuzumab.
    Type: Application
    Filed: December 9, 2016
    Publication date: July 2, 2020
    Applicant: Cedars-Sinai Medical Center
    Inventors: Stanley Jordan, Ashley Vo, Jua Choi
  • CYTOTOXIC AND ANTI-MITOTIC COMPOUNDS, AND METHODS OF USING THE SAME
    Publication number: 20200207865
    Abstract: Compounds having cytotoxic and/or anti-mitotic activity are disclosed. Methods associated with preparation and use of such compounds, as well as pharmaceutical compositions comprising such compounds, are also disclosed. Also disclosed are compositions having the structure: (T)-(L)-(D), wherein (T) is a targeting moiety, (L) is an optional linker, and (D) is a compound having cytotoxic and/or anti-mitotic activity.
    Type: Application
    Filed: July 26, 2019
    Publication date: July 2, 2020
    Inventors: Geoffrey WINTERS, James RICH, Graham GARNETT, Alexander MANDEL, Tom HSIEH, Elyse BOURQUE, Stuart BARNSCHER
  • ANTI-TLR4 ANTIBODIES AND USES THEREOF
    Publication number: 20200207866
    Abstract: Disclosed are antibodies that specifically bind Toll-like Receptor 4 (TLR-4), and to methods of using the anti-TLR4 antibodies as therapeutics and diagnostic agents.
    Type: Application
    Filed: July 19, 2019
    Publication date: July 2, 2020
    Inventors: Francois Rousseau, Jeremy Loyau, Nicolas Fischer, Greg Elson, Marie Kosco-Vilbois
  • HEAVY CHAIN ANTIBODIES BINDING TO ECTOENZYMES
    Publication number: 20200207867
    Abstract: Human heavy chain antibodies, such as UniAbs™, binding to ectoenzymes are provided along with combinations of such heavy chain antibodies and multi-specific heavy chain antibodies, targeting non-overlapping epitopes on ectoenzymes, including synergistic combinations. Methods of making such antibodies, compositions including pharmaceutical compositions comprising such antibodies, and methods directed to the treatment of disease or conditions associated with the expression of ectoenzymes are also included.
    Type: Application
    Filed: September 13, 2018
    Publication date: July 2, 2020
    Inventors: Starlynn Clarke, Kevin Dang, Shelley Force Aldred, Nathan Trinklein, Wim van Schooten
  • HER3 BINDING AGENTS AND USES THEREOF
    Publication number: 20200207868
    Abstract: The disclosure is directed to antibodies and binding fragments thereof that specifically bind HER3. The disclosure is further directed to immunoconjugates comprising the antibodies and binding fragments thereof that specifically bind HER3. The disclosure is also directed to uses of the antibodies, binding fragments thereof and immunoconjugates for detecting HER3-expressing cells and for treating HER3-expressing cancer.
    Type: Application
    Filed: August 9, 2018
    Publication date: July 2, 2020
    Inventors: Bharathikumar Vellalore Maruthachalam, Aynan Elsayed Mohammad, Jianghai Liu, Humphrey Fonge, Kris Barreto, Clarence Ronald Geyer
  • ANTI-VWF D'D3 SINGLE-DOMAIN ANTIBODIES AND POLYPEPTIDES COMPRISING THEREOF
    Publication number: 20200207869
    Abstract: The invention relates to isolated single-domain antibodies (sdAb) directed against von Willebrand Factor (VWF) D?D3 domain and chimeric polypeptides comprising thereof such as blood clotting factors and their uses in therapy such as in the prevention and treatment of hemostatic disorders. The invention also relates to a method of extending or increasing half-life of a therapeutic polypeptide comprising a step of adding to the polypeptide sequence of said therapeutic polypeptide at least one sdAb directed against VWF D?D3 domain.
    Type: Application
    Filed: March 13, 2020
    Publication date: July 2, 2020
    Inventors: Petrus LENTING, Gabriel AYME, Cecile DENIS, Olivier CHRISTOPHE
  • NEUKINASE, A DOWNSTREAM PROTEIN OF NEUREGULIN
    Publication number: 20200207870
    Abstract: The present invention relates to neukinase, a downstream protein kinase in the neuregulin signaling pathway. In certain aspects, the present invention provides isolated neukinase-encoding nucleic acids, neukinase polypeptides, oligonucleotides that hybridize to neukinase nucleic acids, and expression vectors containing neukinase-encoding sequences. The present invention further provides isolated host cells, antibodies, transgenic non-human animals, compositions, and kits relating to neukinase. In other aspects, the present invention further provides methods of identifying predisposition to cardiac dysfunction, methods of detecting the presence of neukinase, neukinase nucleic acid, methods of screening for agents which affect neukinase activity, and methods of modulating neukinase activity.
    Type: Application
    Filed: February 8, 2019
    Publication date: July 2, 2020
    Inventor: Mingdong Zhou
  • Inhibition of Vascular Matrix Metalloproteinase-9 to Treat Ischemic Injury
    Publication number: 20200207871
    Abstract: Methods and pharmaceutical compositions for treating ischemic injury are provided. The methods include administering a therapeutically effective amount of a vascular matrix metalloproteinase 9 (MMP-9) inhibitor that reduces ischemic injury in a subject.
    Type: Application
    Filed: June 27, 2018
    Publication date: July 2, 2020
    Inventor: Guy L. Reed
  • METHODS FOR TREATING INFLAMMATION AND RELATED DISEASES AND DISORDERS BY INHIBITING ALPHA PROTEIN KINASE 1
    Publication number: 20200207872
    Abstract: The disclosure provides methods related to inhibiting alpha-kinase 1 (ALPK1) for treating inflammation and inflammatory diseases, disorders, and conditions, as well as for treating an autoimmune disease, a disease or disorder caused by a bacterial infection, or cancer.
    Type: Application
    Filed: July 4, 2018
    Publication date: July 2, 2020
    Inventors: Tian Xu, Tongruei Raymond Li, Cong Xu, Jieqing Fan, Danyang Liu, Yanfang Pan
  • ANTIBODIES AND PEPTIDES TO TREAT HCMV RELATED DISEASES
    Publication number: 20200207873
    Abstract: The present invention relates to the treatment of HCMV relates diseases. The inventors conducted a study to find an essential domain of pUL56 for its interaction with pUL89 which is important in the effect of the CMV. Sequences alignments allowed them to predict one sequence in C-terminal of pUL56 potentially necessary for interaction with pUL89. BAC mutagenesis and AlphaLISA technologies using purified proteins allowed to validate that the short sequence 671WMVVKYMGFF680 (SEQ ID NO: 1) in C-terminal of pUL56 is involved in interaction with pUL89. Knowing this important information, antibodies directed against this sequence or peptides derived from this sequence could be useful to invalidate the interaction of pUL56 to pUL89 and thus to treat HCMV related diseases.
    Type: Application
    Filed: July 19, 2018
    Publication date: July 2, 2020
    Inventors: Sophie ALAIN, Gaëtan LIGAT, Sébastien HANTZ, Anthony COUVREUX
  • POLYPEPTIDE-POLYNUCLEOTIDE-COMPLEX AND ITS USE IN TARGETED EFFECTOR MOIETY DELIVERY
    Publication number: 20200207874
    Abstract: Herein is reported a polypeptide-polynucleotide-complex as therapeutic agent and its use as tool for the targeted delivery of an effector moiety. The polynucleotide part of the complex is essentially resistant to proteolytic and enzymatic degradation in vivo. Additionally the polypeptide part specifically binds to a compound or structure such as a tissue or organ, a process or a disease. Thus, one aspect as reported herein is a polypeptide-polynucleotide-complex comprising a) a polypeptide specifically binding to a target and conjugated to a first member of a binding pair, b) a polynucleotide linker conjugated at its first terminus to the second member of the binding pair, and c) an effector moiety conjugated to a polynucleotide that is complementary to at least a part of the polynucleotide linker.
    Type: Application
    Filed: December 5, 2019
    Publication date: July 2, 2020
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Michael GERG, Dieter HEINDL, Gerhard NIEDERFELLNER, Wolfgang SCHAEFER, Michael SCHRAEML, Michael TACKE
  • METHOD FOR PREPARING RECOMBINANT PROTEIN FROM BACTERIUM AND COMPOSITION CONTAINING THE SAME
    Publication number: 20200207875
    Abstract: Methods for preparing a recombinant protein from a bacterium are provided. The method includes constructing an expression vector including two promoters. Each of the two promoters attaches a secretion signal peptide to one polypeptide of a protein. The protein attached with the two promoters and secretion signal peptides is then cloned into the expression vector to provide a recombinant expression plasmid. The recombinant expression plasmid is transformed into a host cell. A fermentation process is performed to grow the host cell and to induce an expression to synthesize polypeptides in the host cell and to transport the polypeptides to an outside of a cytoplasm of the host cell, such that the polypeptides are released in a soluble form in a growth medium of the host cell. The polypeptides are assembled into a three-dimensional structure of the protein. The protein is captured from the growth medium.
    Type: Application
    Filed: December 31, 2018
    Publication date: July 2, 2020
    Inventors: Cedric CAGLIERO, Andrew BURNETTE, Yueqing XIE, Hua JIANG, Jianwei ZHU, Huili LU, Manyu LUO
  • Nanocomposite bacteriostatic material and a preparation method and an application thereof
    Publication number: 20200207876
    Abstract: The present invention discloses a novel nano-composite antibacterial material and a preparation method and an application thereof, and belongs to the technical field of preservative materials. The novel nano-composite antibacterial material disclosed by the present invention is prepared by mixing a dimethylimidazole solution, deionized water and a zinc nitrate solution to prepare a metal-organic framework carrier, compositing with nisin to form a nano antibacterial composite material, separating out from a solution in a precipitate form, centrifuging, removing a supernatant, cleaning and re-suspending with the deionized water. The novel nano-composite antibacterial material prepared by the present invention has an antibacterial effect superior to nisin having a same concentration.
    Type: Application
    Filed: March 12, 2020
    Publication date: July 2, 2020
    Inventors: Shiru Jia, Jiandong Cui, Zhilei Tan, Cheng Zhong, Yang Liu, Qiaozhen Luo, Xiaona Li, Yuxiao Feng, Baoting Sun, Le Zhong
  • Thermally Inhibited Starch and Process for Making
    Publication number: 20200207877
    Abstract: Improved thermally inhibited starch is disclosed and methods of making such starch are disclosed. In some embodiments a thermally inhibited starch has improved whiteness and flavor. In some embodiments a method for making a thermally inhibited starch includes providing adding a buffer and an acid to a starch to obtain a pH adjusted starch having an acidic pH and thermally inhibiting the pH adjusted starch. The technology further pertains to methods of making the thermally inhibited starch in batch, continuous, continuous-like process or combinations thereof.
    Type: Application
    Filed: December 18, 2019
    Publication date: July 2, 2020
    Inventors: Christopher Lane, Kamlesh Shah, Tarak Shah
  • AMYLASE-DEGRADED ORGANIC ACID ANHYDRIDE SUBSTITUTED STARCHES AND METHODS OF PREPARING THE SAME
    Publication number: 20200207878
    Abstract: Water soluble, lipophilic starches are provided, which comprise a mixture of functionalized high and low molecular weight maltodextrin molecules. The starches may be formed by dispersing a granular starch in a liquid medium to form a slurry that is simultaneously cooked and subjected to enzyme hydrolysis. Following hydrolysis, the starch is functionalized with an organic acid anhydride reagent, such as octenylsuccinic anhydride. The organic acid anhydride substitution occurs randomly and at various locations within the maltodextrin molecules.
    Type: Application
    Filed: December 27, 2019
    Publication date: July 2, 2020
    Inventors: Yong-Cheng Shi, Yanjie Bai, Zhenhua Sun
  • POLYMERIZATION REACTOR SYSTEM COMPRISING AT LEAST ONE WITHDRAWAL VALVE
    Publication number: 20200207879
    Abstract: Described herein is a polymerization reactor system comprising at least one loop reactor and/or at least one transfer line, and further comprising at least one withdrawal valve, wherein the at least one withdrawal valve is mounted to a wall of a lower horizontal segment of the loop reactor and/or to a wall of the transfer line, at an angle ? of more than 0° and equal to or less than 85°, determined from perpendicular to a tangent of the wall at the mounting position in flow direction of a slurry in the loop reactor and/or in the transfer line.
    Type: Application
    Filed: November 2, 2018
    Publication date: July 2, 2020
    Inventors: Christof Wurnitsch, Sameer Vijay, Erno Elovainio
  • METHOD FOR PRODUCING MODIFIED POLYTETRAFLUOROETHYLENE, METHOD FOR PRODUCING MODIFIED POLYTETRAFLUOROETHYLENE POWDER, AND METHOD FOR PRODUCING STRETCHED POROUS MATERIAL
    Publication number: 20200207880
    Abstract: To provide a novel method for producing a modified PTFE. The method for producing a modified polytetrafluoroethylene comprises polymerizing tetrafluoroethylene in an aqueous medium in which a polymer comprising units based on a fluorine-free monomer is present.
    Type: Application
    Filed: March 10, 2020
    Publication date: July 2, 2020
    Applicant: AGC Inc.
    Inventors: Shinya HIGUCHI, Shiro EBATA, Takehiro KOSE
  • LIQUID COMPOSITION, DEVICE, METHOD OF MANUFACTURING POROUS RESIN, POROUS RESIN, PRODUCT, AND METHOD OF MANUFACTURING POROUS RESIN
    Publication number: 20200207881
    Abstract: A liquid composition that contains a polymerizable compound and a solvent, and that can form a porous resin. The liquid composition, when stirred, transmits at least 30 percent of incident light having a wavelength of 550 nm. The haze value of an containing the liquid composition increases by 1.0 percent or more when the element containing the liquid composition is cured.
    Type: Application
    Filed: December 26, 2019
    Publication date: July 2, 2020
    Inventors: Miku OHKIMOTO, Keigo TAKAUJI, Hideo YANAGITA, Toru USHIROGOCHI
  • Multiple Reactor and Multiple Zone Polyolefin Polymerization
    Publication number: 20200207882
    Abstract: Apparatuses and processes that produce multimodal polyolefins, and in particular, polyethylene resins, are disclosed herein. This is accomplished by using two reactors in series, where one of the reactors is a multi-zone circulating reactor that can circulate polyolefin particles through two polymerization zones optionally having two different flow regimes so that the final multimodal polyolefin has improved product properties and improved product homogeneity.
    Type: Application
    Filed: December 27, 2018
    Publication date: July 2, 2020
    Inventors: Joseph A. CURREN, Rebecca A. GONZALES, Scott E. KUFELD, Joel A. MUTCHLER, Eric J. NETEMEYER, Jamie N. SUTHERLAND, Paul J. DESLAURIERS, Jeff S. FODOR